Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, COVID-19 immunisation, Interchange of vaccine products, Psoriasis, Therapeutic product effect decreased
Clinical narrative: Felt that the Skyrizi made plaque psoriasis a little better at first but was resulting back to square one/was not making it better anymore; Felt that the Skyrizi made plaque psoriasis a little better at first but was resulting back to square one/was not making it better any more; Revaccination with different COVID-19 vaccine; INTERCHANGE OF VACCINE PRODUCTS; COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of PSORIASIS (Felt that the Skyrizi made plaque psoriasis a little better at first but was resulting back to square one/was not making it better anymore), COVID-19 (COVID-19), THERAPEUTIC PRODUCT EFFECT DECREASED (Felt that the Skyrizi made plaque psoriasis a little better at first but was resulting back to square one/was not making it better any more), COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) and INTERCHANGE OF VACCINE PRODUCTS (INTERCHANGE OF VACCINE PRODUCTS) in a 49-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. MPID: 4782589) for COVID-19 vaccination.    Co-suspect product included non-company product RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) solution for injection for Plaque psoriasis.    Concurrent medical conditions included Plaque psoriasis (Moderate to Severe Chronic Plaque Psoriasis). Concomitant products included TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.   On 21-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) UNK, Solution for Injection, Single-Dose Prefilled Syringe with Needle Guard. In 2021, the patient experienced COVID-19 (COVID-19). On an unknown date, the patient experienced PSORIASIS (Felt that the Skyrizi made plaque psoriasis a little better at first but was resulting back to square one/was not making it better anymore), THERAPEUTIC PRODUCT EFFECT DECREASED (Felt that the Skyrizi made plaque psoriasis a little better at first but was resulting back to square one/was not making it better any more), COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) and INTERCHANGE OF VACCINE PRODUCTS (INTERCHANGE OF VACCINE PRODUCTS). At the time of the report, PSORIASIS (Felt that the Skyrizi made plaque psoriasis a little better at first but was resulting back to square one/was not making it better anymore) outcome was unknown, COVID-19 (COVID-19), COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) and INTERCHANGE OF VACCINE PRODUCTS (INTERCHANGE OF VACCINE PRODUCTS) had resolved and THERAPEUTIC PRODUCT EFFECT DECREASED (Felt that the Skyrizi made plaque psoriasis a little better at first but was resulting back to square one/was not making it better any more) had not resolved.    The reporter's causality for the event(s) of Covid-19 and Felt that the Skyrizi made plaque psoriasis a little better at first but was resulting back to square one/was not making it better any more with Risankizumab Solution for Injection was Not Provided. The reporter's causality for the event(s) of Felt that the Skyrizi made plaque psoriasis a little better at first but was resulting back to square one/was not making it better any more with Risankizumab Solution for Injection was Reasonable Possibility.  It was unknown if patient was enrolled in COVID-19-Vaccine Trial.  No treatment information was reported.